Talent Pool

Contributed by:

PharmaVOICE Staff

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Biotechnology Pool

PV0315_TonyHuntTony Hunt
Repligen Names CEO
Repligen, a life-sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs, has appointed Tony Hunt as CEO. Mr. Hunt, currently Repligen’s chief operating officer, will succeed Walter Herlihy, Ph.D., who will retire as president and CEO effective May 21, 2015.
Before his role as chief operating officer at Repligen, Mr. Hunt was president, bioproduction at Life Technologies, a global life-sciences company.

PV0315_DrDeborahLawDr. Deborah Law
Jounce Therapeutics Appoints Chief Scientific Officer
Jounce Therapeutics, a company focused on the discovery and development of novel cancer immunotherapies coupled to patient selection strategies, has appointed Deborah Law, D. Phil., to the position of chief scientific officer. Dr. Law brings to Jounce nearly two decades of experience in biologics drug discovery and development, particularly in the fields of oncology and immunology.
Dr. Law joins Jounce from Merck, where she most recently served as VP of therapy area biology for immunology, oncology, and immunomodulators.

PV0315_DrLitchmanDr. Manuel Litchman
Arvinas Appoints President and CEO
Arvinas, a biotechnology company creating a new class of oncology drugs based on protein degradation, has appointed Manuel Litchman, M.D., as president and CEO. Dr. Litchman was most recently senior VP and global program head at Novartis Pharmaceuticals.
Before joining Arvinas, Dr. Litchman spent more than 18 years with Novartis Pharmaceuticals, serving in multiple positions of increasing responsibility, focusing on oncology.

Biopharma Pool

PV0315_GregMadisonGreg Madison
Keryx Biopharmaceuticals Announces Transition of Leadership
Keryx Biopharmaceuticals is transitioning the role of CEO from Ron Bentsur to its current Chief Operating Officer Greg Madison. Mr. Bentsur has led Keryx for the past five years, culminating in the approval and year-end 2014 launch of Auryxia (ferric citrate). Mr. Madison also has been appointed president.
Before joining Keryx, Mr. Madison served as the executive VP and chief commercial officer of AMAG Pharmaceuticals.

Michael Bailey
Dr. Michael Needle
PV0315_DrMichaelNeedleAVEO Makes Management Changes
AVEO Oncology has appointed Michael Bailey as president and CEO. Mr. Bailey, who currently serves as chief business officer of AVEO, succeeds Tuan Ha-Ngoc, who will become chairman of AVEO’s board of directors.
In other company news, Michael Needle, M.D., has been appointed to the position of chief medical officer. In this role, Dr. Needle, a board certified hematologist/oncologist, will take a leadership role in evaluating clinical development strategies for advancement of the company’s partnered and proprietary pipeline programs.

Agency Pool

PV0315_VinKalathiveetilVin Kalathiveetil
Anneliese Schrotenboer
GA Communications Expands Team
GA Communication Group, a full-service healthcare marketing agency, has made a range of staff additions and hires.
Vin Kalathiveetil joins the agency’s client service team as senior account director from the Hobart Core, where he served as a group account supervisor.

Anneliese Schrotenboer also joined the GA client service team as an account director. Most recently, she was at Pfizer Pharmaceuticals where she PV0315_AnnelieseSchroteboerwas the primary lead for the strategic planning, execution, analysis, and optimization of all professional multi-channel marketing campaigns for U.S. oncology brands.

CRO Pool

Dr. Michael Gibertini
Alistair Macdonald


INC Research, a global Phase I to IV contract research organization, has promoted Michael Gibertini, Ph.D., president and general manager, central nervous system (CNS) clinical development, to the newly created role of president, clinical development.

Alistair Macdonald, who has served as the company’s chief operating officer (COO) since January 2013, has been promoted to president and chief operating officer.

Dennis Kinsey
PV0315_DennisKinseyPharma Tech Industries Hires Director of Business Development
Pharma Tech Industries, a pharmaceutical contract manufacturer and packager of powder products, has named Dennis Kinsey as director of business development.  With more than 30 years of industry experience, Mr. Kinsey has applied his supply chain and operations expertise at such companies as Johnson & Johnson, GlaxoSmithKline’s Consumer Healthcare division, AstraZeneca and, most recently, Insight Pharmaceuticals.

Consulting Pool

PV0315_LeeAnnAliLeeAnn Ali
BioBridges Names Executive Director, Clinical Operations
BioBridges, a contract consulting company servicing the pharma, biotech, and medical device industries, has hired LeeAnn Ali as executive director, clinical operations.

She has led clinical affairs and operations for many prominent pharmaceutical, medical device organizations, and CROs.

Technology Pool

PV0315_CarterHollandCarter Holland
Michael Owings
Lisa Reinhold
TraceLink Expands Executive Management Team
Carter Holland had been named chief marketing officer of TraceLink, a company specializing in protecting patient safety. Mr. Holland is a 20-year technology veteran who has led global marketing teams through aggressive periods of organic and M&A growth, business transformation, and brand reinvention.

PV0315_MichaelOwingsMichael Owings has been named VP of compliance. For the past 20 years, he has successfully implemented effective regulatory compliance, privacy, quality and security frameworks for a range of industry-leading companies.

In other company news, Lisa Reinhold has been named VP of global network and customer success. Ms. reinhold is an entrepreneurial customer service executive with 25-years of experience transforming, developing, and building global service and support organizations.

Gavin Nichols
Certara Appoints President of Technology
PV0315_GavinNicholsCertara, a global biosimulation technology-enabled drug development and drug safety consulting company, has appointed Gavin Nichols to the newly created position of president of technology. Mr. Nichols also serves as the head of Certara’s software business unit and is based in its Cary, N.C., office.

In his new position, Mr. Nichols leads Certara’s R&D, product management, and IT teams, and is responsible for the development and positioning of the company’s biosimulation applications and informatics platforms across the life-sciences spectrum — from discovery through development to patient care. He joins Certara from Quintiles where he served as VP of strategy/enterprise architecture/R&D innovation IT. (PV)

Posted in:

Post a Comment

You must be logged in to post a Comment.